Perianal And Anal Sac Cancers In Dogs And Cats

Perianal and anal sac cancers are relatively common in dogs and less frequent in cats, but when they occur, they can be invasive and clinically significant. The most common tumour in this category is anal sac adenocarcinoma (apocrine gland adenocarcinoma of the anal sac) in dogs, which is highly malignant and often associated with paraneoplastic hypercalcemia.

Other perianal tumours include perianal gland adenomas (usually benign), perianal gland carcinomas, and less common soft tissue sarcomas. In cats, tumours in this region are rare but can include adenocarcinomas and lymphomas.

These cancers can cause severe local disease by invading surrounding tissues of the pelvis and hindquarters, and anal sac adenocarcinoma in particular has a strong tendency to metastasise to lymph nodes, lungs, and abdominal organs. Early recognition and precise staging are vital to guide treatment.

Common signs of perianal and anal sac cancers include:

• Swelling or a lump near the anus.
• Scooting, straining, or difficulty passing stool.
• Pain or discomfort in the hind end.
• Constipation or changes in stool shape.
• Excessive licking of the perineal region.
• Increased thirst and urination due to hypercalcemia (in anal sac adenocarcinoma).

Diagnosis involves rectal examination, fine needle aspirates, biopsy, bloodwork (to check calcium levels), ultrasound, and CT. However, conventional imaging may miss small metastases or underestimate lymph node involvement. PET-CT adds a powerful dimension by revealing functional disease activity throughout the body.

These cancers often spread before clinical signs are apparent, and local invasion can be difficult to assess. PET-CT provides anatomical detail and metabolic mapping, critical for accurate staging.

Primary benefits include:

• Whole-body staging detects spread to sublumbar lymph nodes, lungs, liver, and other organs.
• Differentiating tumour from inflammation: Clarifies whether enlarged lymph nodes are malignant or reactive.
• Defines tumour margins and metastatic involvement, helping surgeons plan resections or lymph node excisions.
• Radiation therapy guidance by identifying the most active tumour areas for targeted dosing while sparing surrounding pelvic tissues.
• Tracks metabolic response during chemotherapy, radiation, or combined treatments.
• Provides clarity about tumour aggressiveness and disease extent, guiding owner discussions.

These tumours are often invasive and metastatic, accurate staging and careful treatment planning are essential to managing outcomes. PET Theranostics provides vets with diagnostic clarity, supports confident treatment decisions, and facilitates transparent communication with clients.
By incorporating PET-CT into the management of perianal and anal sac cancers, vets can detect hidden spread earlier, target treatment and guide owners through the decision-making process. These tumours are common in dogs and pet owners can speak directly to their primary vet about a referral to Pet Theranostics.